Skip to content
No. 021Ruled outNeglected diseases of povertyUpdated Nov 15, 2026

Finding the villages where ivermectin treatment for river blindness is safe to give, in areas where loiasis is also common

Good it would do
2 / 5
Can AI help
2 / 5
How neglected
3 / 5
Can we check it
3 / 5

Why we stopped

Rejected on prior art and tractability: the Lancaster/Manchester group (Johnson, Giorgi, Diggle) already models where ivermectin is safe in Loa co-endemic areas, and its 2026 Nigeria repository does the scout's exact extreme-value, satellite-covariate, held-out model; the public intensity data are one 92-village Gabon subset, so progress in the hypoendemic areas that matter needs new LoaScope surveys and custodian data, not compute.

Why it's stuck

Ivermectin is the main medicine for river blindness, but people who also carry very heavy loiasis infections can have serious reactions to it, so mass treatment is held back where the two diseases overlap. A 2019 projection across 14 West and Central African countries estimated that about 31,000 people with both infections and very high loiasis levels would still need treatment in 2025, and that 92.8 percent of them live in low-transmission areas that mass treatment programs do not target.

What we'd try

Build village-level risk maps of very heavy loiasis infection by combining the published pre-control prevalence surveys for both diseases with satellite data on forest cover, land use and climate, and estimate the uncertainty for each village. The check is to hold back villages that have since been screened person by person under the test-and-not-treat approach and see whether the map predicts the share of heavily infected people there.

Source: https://pubmed.ncbi.nlm.nih.gov/31304961/

Think we got it wrong?

Ruled-out problems can come back. Tell us what we missed.

Members can read the full record for this problem, check its sources and comment. Open the member view →